This is a primer to get you thinking about whether or not your mobile health app is going to need FDA approval. If you are just tripping across the internet and found this, check the date, this was given before the FDA finalized their guidelines.
This presentation looks at some of the unique considerations in developing mobile programs, especially apps. A significant amount of the presentation is dedicated to elucidating and expanding on the FDA's recently finalized guidance regarding mobile medical apps.
This deck was presented at the 2013 Food & Drug Law Institute's Advertising & Promotion conference. I provided advice to people responsible for the selection and/or upgrade of electronic promotional review systems used in the review and approval of marketing materials for prescription products.
With the explosion of social media and its growing importance, it’s critical for those in the pharmaceutical industry to understand how to leverage social networks compliantly to see positive results and minimize risk. If, and when, the FDA guidance on social media is final, questions will remain. This presentation helps the audience incorporate the latest social media technologies into acceptable and successful communications and marketing plans. Focus is given to regulatory requirements, types of communications, responsiveness, and dealing with adverse events.
Regulatory Considerations in Mobile ProgramsDale Cooke
This presentation looks at some of the unique considerations in developing mobile programs, especially mobile apps. A significant amount of the presentation is dedicated to elucidating and expanding on the FDA's recently finalized guidance regarding mobile medical apps. Topics covered include:
* FDA’s finalized Mobile Medical Applications—Guidance for Industry and Food and Drug Administration Staff
* Determination of whether a mobile app is a medical device subject to FDA enforcement action
* Scope of FDA’s regulatory discretion regarding mobile apps
* FDA’s conflicting guidance on dosage apps
* How to meet key requirements of promotional labeling in mobile programs
* The growing area of mobile apps as promotional messaging platforms
This presentation has appeal for anyone interested in adopting mobile tactics, whether that interest is in developing medical devices or making use of mobile tactics to promote pharmaceuticals or biologics.
The framework flow chart shown in this presentation is available here: http://ow.ly/qMxse
DIA Marketing Pharmaceuticals 2015 Leveraging Innovative TechnologiesDale Cooke
This is the slide deck I used to introduce a session on how sponsors of prescription drugs, biologics, and medical devices can take advantage of the newer means that both consumers and healthcare professionals are using to access information, while remaining compliant with FDA regulations.
This presentation looks at some of the unique considerations in developing mobile programs, especially apps. A significant amount of the presentation is dedicated to elucidating and expanding on the FDA's recently finalized guidance regarding mobile medical apps.
This deck was presented at the 2013 Food & Drug Law Institute's Advertising & Promotion conference. I provided advice to people responsible for the selection and/or upgrade of electronic promotional review systems used in the review and approval of marketing materials for prescription products.
With the explosion of social media and its growing importance, it’s critical for those in the pharmaceutical industry to understand how to leverage social networks compliantly to see positive results and minimize risk. If, and when, the FDA guidance on social media is final, questions will remain. This presentation helps the audience incorporate the latest social media technologies into acceptable and successful communications and marketing plans. Focus is given to regulatory requirements, types of communications, responsiveness, and dealing with adverse events.
Regulatory Considerations in Mobile ProgramsDale Cooke
This presentation looks at some of the unique considerations in developing mobile programs, especially mobile apps. A significant amount of the presentation is dedicated to elucidating and expanding on the FDA's recently finalized guidance regarding mobile medical apps. Topics covered include:
* FDA’s finalized Mobile Medical Applications—Guidance for Industry and Food and Drug Administration Staff
* Determination of whether a mobile app is a medical device subject to FDA enforcement action
* Scope of FDA’s regulatory discretion regarding mobile apps
* FDA’s conflicting guidance on dosage apps
* How to meet key requirements of promotional labeling in mobile programs
* The growing area of mobile apps as promotional messaging platforms
This presentation has appeal for anyone interested in adopting mobile tactics, whether that interest is in developing medical devices or making use of mobile tactics to promote pharmaceuticals or biologics.
The framework flow chart shown in this presentation is available here: http://ow.ly/qMxse
DIA Marketing Pharmaceuticals 2015 Leveraging Innovative TechnologiesDale Cooke
This is the slide deck I used to introduce a session on how sponsors of prescription drugs, biologics, and medical devices can take advantage of the newer means that both consumers and healthcare professionals are using to access information, while remaining compliant with FDA regulations.
Here is the slideset I presented at the 2nd International Conference on Business Analytic and Intelligence (ICBAI). The intent behind the paper/presentation was to bring out awareness on AE analysis and present status of AE data in india. Certainly there are huge potential benefit/insights out of this data if the base is set well. Private health care institutions can reap the benefit (Both financial and patient care) if they invest to define the system for their use.
Cloud-Based My Health Records Software – Anytime, Anywhere, and Easy Access to varied devices. Handily manage your health details with 75Health.
https://www.75health.com/my-health-record.jsp
NEST – Improving the Regulatory Process for Medical DevicesEMMAIntl
Innovating the medical device regulatory process is a goal that the FDA’s Center for Devices and Radiological Health (CDRH) is constantly striving towards. Among several other programs introduced or changed over the past couple years, the National Evaluation System for Health Technology (NEST) is a program the FDA is building upon to generate better real-world evidence to guide their decision-making around medical devices...
This Slide talks about Apple's ResearchKit which is an open source framework introduced by Apple that allows researchers and developers to create powerful apps for medical research
1) Optimising business process for telehealth services
2) Business process management in healthcare
3) Medical claim for healthcare (EDI 837)
4) Remote patients monitoring system
5) Noval drug approval for 2021 (FDA)
6) How covid-19 accelerated healthcare
Presentation - Mobile Medical Applications Guidance for Industry and Food and...Jason Haislmaier
Presentation to PrIME Health Collaborative at Galvanize in Denver, Colorado on October 29, 2013 covering an overview of the FDA "Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff."
The competitiveness of drug development has been the impetus for new and accelerated regulatory pathways. While the growing patient-centric healthcare market coupled with a vested interest in safety information from a range of governmental and regulatory stakeholders has driven pharmacovigilance to reach a new paradigm in drug development. The consequence of which has led to tighter post-marketing surveillance systems on the global scale and a rapidly expanding volume of reported safety events impelling the industry to adopt new strategies to managing pharmacovigilance throughout the product lifecycle. In view of all these changes, it is timely to provide an overview on the concept of Pharmacovigilance, and here i3 Consult has published in this Slide Share, some key topics on Pharmacovigilance such as Signal Detection, Detection Management, Risk Management and Risk Reduction Strategies. At i3 Consult, our core team of experts & our 200,000+ network bring innovative ideas, cost effective solutions and game changing services to healthcare, pharma & life science, for more details, visit www.i3consult.com
Matteo Crippa: ResearchKit: an open source framework by Apple for medical re...Mobile Trends
Matteo Crippa - ResearchKit - an open source framework by Apple for medical research.
During early 2015 Apple has released an awesome open source framework to allow researchers and developers to create powerful apps for medical research and clinical trials. Are you ready to improve the framework with a pull request and help other people’s life?
Mobile Medical Apps and FDA Regulatory ApproachAkshay Anand
A presentation on Food Safety and Standards Authority of India. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during March 2015
mHealth Israel_Digital Health Regulation and the FDALevi Shapiro
Presentation by Bethany Hills, Partner, Mintz Levin: Digital Health Regulation and the FDA. Includes overview of the 21st Century Cures Act, Definition of a medical device, device approval basics, software as a Medical Device (SaMD), FDA Digital Health Activities, mobile medical applications, regulated mobile medical applications, Enforcement discretions of MMA, Clinical Decision Support, 3060 Clarifying Health Software Regulation, Classification Process,
Here is the slideset I presented at the 2nd International Conference on Business Analytic and Intelligence (ICBAI). The intent behind the paper/presentation was to bring out awareness on AE analysis and present status of AE data in india. Certainly there are huge potential benefit/insights out of this data if the base is set well. Private health care institutions can reap the benefit (Both financial and patient care) if they invest to define the system for their use.
Cloud-Based My Health Records Software – Anytime, Anywhere, and Easy Access to varied devices. Handily manage your health details with 75Health.
https://www.75health.com/my-health-record.jsp
NEST – Improving the Regulatory Process for Medical DevicesEMMAIntl
Innovating the medical device regulatory process is a goal that the FDA’s Center for Devices and Radiological Health (CDRH) is constantly striving towards. Among several other programs introduced or changed over the past couple years, the National Evaluation System for Health Technology (NEST) is a program the FDA is building upon to generate better real-world evidence to guide their decision-making around medical devices...
This Slide talks about Apple's ResearchKit which is an open source framework introduced by Apple that allows researchers and developers to create powerful apps for medical research
1) Optimising business process for telehealth services
2) Business process management in healthcare
3) Medical claim for healthcare (EDI 837)
4) Remote patients monitoring system
5) Noval drug approval for 2021 (FDA)
6) How covid-19 accelerated healthcare
Presentation - Mobile Medical Applications Guidance for Industry and Food and...Jason Haislmaier
Presentation to PrIME Health Collaborative at Galvanize in Denver, Colorado on October 29, 2013 covering an overview of the FDA "Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff."
The competitiveness of drug development has been the impetus for new and accelerated regulatory pathways. While the growing patient-centric healthcare market coupled with a vested interest in safety information from a range of governmental and regulatory stakeholders has driven pharmacovigilance to reach a new paradigm in drug development. The consequence of which has led to tighter post-marketing surveillance systems on the global scale and a rapidly expanding volume of reported safety events impelling the industry to adopt new strategies to managing pharmacovigilance throughout the product lifecycle. In view of all these changes, it is timely to provide an overview on the concept of Pharmacovigilance, and here i3 Consult has published in this Slide Share, some key topics on Pharmacovigilance such as Signal Detection, Detection Management, Risk Management and Risk Reduction Strategies. At i3 Consult, our core team of experts & our 200,000+ network bring innovative ideas, cost effective solutions and game changing services to healthcare, pharma & life science, for more details, visit www.i3consult.com
Matteo Crippa: ResearchKit: an open source framework by Apple for medical re...Mobile Trends
Matteo Crippa - ResearchKit - an open source framework by Apple for medical research.
During early 2015 Apple has released an awesome open source framework to allow researchers and developers to create powerful apps for medical research and clinical trials. Are you ready to improve the framework with a pull request and help other people’s life?
Mobile Medical Apps and FDA Regulatory ApproachAkshay Anand
A presentation on Food Safety and Standards Authority of India. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during March 2015
mHealth Israel_Digital Health Regulation and the FDALevi Shapiro
Presentation by Bethany Hills, Partner, Mintz Levin: Digital Health Regulation and the FDA. Includes overview of the 21st Century Cures Act, Definition of a medical device, device approval basics, software as a Medical Device (SaMD), FDA Digital Health Activities, mobile medical applications, regulated mobile medical applications, Enforcement discretions of MMA, Clinical Decision Support, 3060 Clarifying Health Software Regulation, Classification Process,
Digital Therapeutics Regulatory Process, Update and TrendsInsights10
The market for digital therapeutics (DTx) is expanding tremendously, aided by the increased popularity of decentralized medicine that the pandemic brought about. The global market for DTx was predicted to be worth $3.35 billion in 2021 and would grow to $12.1 billion by 2026. To get a report in detail, contact us at - info@insights10.com
The global market for mobile apps is valued at 25 billion dollars. The market for health apps in particular is booming; the FDA predicts 500 million smartphone users will use a mobile medical app this year, and the number is expected to rise to 1.7 billion by 2018. In the past, medical software has been regulated using the same model as medical devices.
Recently, the FDA realized it needed a new and different approach to support a rising number of apps, especially those aimed at patients. In addition to the rapid growth of the market, some health app developers have made claims that can’t be supported. This prompted the FDA to issue a new guidance in February of this year.
View the presentation to learn more about the FDA's Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff including:
1. Key points of differentiation between health apps and mobile medical apps
2. The common mistake developers make when defining their product
3. What developers of non-regulated health apps should avoid when marketing their application
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Do you have a medical device that treats or diagnoses a life-threatening disease? If yes, your device may be eligible for an expedited review pathway called the Breakthrough Devices Program. The FDA defines a breakthrough device as any device (or device-led combination product) that will “provide for more effective treatment or diagnosis of life-threatening or irreversibility debilitating diseases or conditions”...
A Survey on Current Applications for Tracking COVID-19EMMAIntl
The COVID-19 pandemic is still creating headlines in the health care domain. Around the world, governments, and organizations such as World Health Organization (WHO), European Medical Agency (EMA), and FDA are working together to eliminate lockdowns and get our society back up and running. In such cases, several companies, firms, and universities have found opportunities to provide critical services such as virus detection, tracking, data-driven decision-making algorithms, and visual analytic applications...
Recent FDA Developments in Digital Health & Clinical Decision Support SoftwareMichael Swit
June 7, 2018 presentation at the 4th Annual Medical Device Summit, sponsored by ComplianceOnline, in San Francisco, focusing on the impact of the 21st Century Cures Act and other developments on how FDA regulates software in the medical device arena, including mobile medical applications.
The term Software as a Medical Device is defined by the International Medical Device Regulators Forum (IMDRF) as "software intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device." Use of Software as a Medical Device is continuing to increase.
In this presentation we want to outline the principles of medical device regulations and the 510(k) Premarket notification process for an efficient product approval with the FDA.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
Health 2.0 San Antonio Does your Health APP need FDA Approval?
1. Does your Mobile App need
FDA Approval?
Cynthia Phelps
July 16, 2013
2. Why does the FDA care?
The FDA is charged with protecting and advancing
the public health
Food, Drug and Cosmetic Act of 1938
They regulate:
• Biologics (blood
supply), Cosmetics, Drugs, Food, Radiation
products, Veterinary Products AND
• Medical Devices
3. Software FDA regulates
Medical Device Software
Productions System Software
Quality System Software
Electronic Medical Records Software
Clinical Investigations Software
7. Regulated Products
Grey Area – FDA Guidelines
http://www.fda.gov/MedicalDevices/DeviceRegulationan
dGuidance/GuidanceDocuments/
Not yet approved by Congress
8. What is a Medical Device?
An
instrument, apparatus, implement, machine, contri
vance, implant, in vitro reagent, or similar or
related article, including any component, part, or
accessory, which is intended for the diagnosis, of
disease, or in the cure, mitigation, treatment, or
prevention of disease in man or animals, or
intended to affect the structure of function of the
body of man or animal.
9. Is your App a
Medical Device?
Does your App:
Amplify Cure
Analyze Detect
Interprets Diagnose
Assess Manipulate
Calculate Measure
Control Program
Convert Show trends?
10. What is the intended use?
Is it a part of an existing medical
device?
Is it an extension of a medical
device?
Does it diagnose, treat, mitigate, or
prevent a disease?
12. Extensions of Devices
Apps that serve as extensions of
regulated devices such as those that:
control the devices or
display data from the devices
Analyze data from the devices
Transmit data from these devices
13. Transform Apps to Devices
Apps that serve to transform mobile
platforms into medical control by
using:
Attachments
Similar medical device functions
14. Data Input Devices
Apps allow users to input patient
data to:
Output patient specific results, or
Diagnose
Using formulae or algorithms
15. OMG
Class I Class II Class III
OMG You
better have
stacks of
cash and a
boat load of
patience
It’s ok, you
can ride
someone’s
coattails
No worries
the FDA
have bigger
fish to fry
The Skinny
16. Class I Class II Class III
3+ Years
FDA review
PMA
application
2+ Months
FDA review
510(k)
application
No Formal
Review
Register
Online
Timeline & Process
17. Class III
• Highest risk
• Your app qualifies as a medical device
• There is no existing medical device precedent for
your App
18. Class II
• Medium Risk
• You app counts as a medical device
• There are other FDA approved medical devices like
yours
19. Class I
Lowest Risk
Your App is exempt from pre-market notification
requirements (510(k)) in the US
MDDS – Medical Device Data Systems (2001)
Category of devices used to transfer, store, convert, or display
medical device data.
No diagnosis or treatment
No altering the function or controlling the function of a medical
device
21. FDA Guidelines not Final
FDA, ONC and FCC are developing a report to be
delivered to Congress by September that
includes:
“a strategy for coordinating the regulation of health information
technology in order to avoid regulatory duplication” and
“recommendations on an appropriate regulatory framework for
health information technology, including a risk-based framework.”
Discourage Innovation in Healthcare
Latest news: http://mobihealthnews.com/23305/final-days-of-
waiting-for-fda-mobile-medical-app-guidance/
22. FDA Scorecard
1. Number of FDA regulated medical apps reviewed to date: 100 mobile
medical apps to date (June 2013)
2. Time it takes for apps to get through 510(k): About 67 days for most mobile
medical apps.
3. Number of medical apps seeking clearance each year: FDA only reviews
about 20 mobile medical apps each year through its medical device
regulatory process.
4. No Class III mobile medical apps yet: The FDA has not found any mobile
medical apps to be Class III medical devices yet.
5. When will the final guidance on mobile medical apps be published? That’s a
good question, September.